Ascentage Pharma Group International (NASDAQ:AAPG) & CSL (OTCMKTS:CSLLY) Head-To-Head Contrast

CSL (OTCMKTS:CSLLY) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Volatility and Risk

CSL has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Ascentage Pharma Group International has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of CSL shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for CSL and Ascentage Pharma Group International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CSL	0	2	0	1	2.67
Ascentage Pharma Group International	0	0	6	1	3.14

Ascentage Pharma Group International has a consensus price target of $48.40, suggesting a potential upside of 109.16%. Given Ascentage Pharma Group International’s stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than CSL.

Profitability

This table compares CSL and Ascentage Pharma Group International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CSL	N/A	N/A	N/A
Ascentage Pharma Group International	N/A	N/A	N/A

Earnings and Valuation

This table compares CSL and Ascentage Pharma Group International”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CSL	$15.56 billion	3.14	$3.00 billion	N/A	N/A
Ascentage Pharma Group International	$390.60 million	5.53	-$55.54 million	N/A	N/A

CSL has higher revenue and earnings than Ascentage Pharma Group International.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.